Publications

  1. Hardegree EL, Sachdev A, Villarraga HR, Frantz RP, McGoon MD, Kushwaha SS, Hsiao JF, McCully RB, Oh JK, Pellikka PA, Kane GC. Role of serial quantitative assessment of right ventricular function by strain in pulmonary arterial hypertension. Am J Cardiol. 2013 Jan 1; 111(1):143-8. Epub 2012 Oct 23. 2293393
    View PubMed
  2. Frost AE, Farber HW, Barst RJ, Miller DP, Elliott CG, McGoon MD. Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry. Chest. 2013 Jan; 143(1):185-95. 2303986
    View PubMed
  3. Swetz KM, Shanafelt TD, Drozdowicz LB, Sloan JA, Novotny PJ, Durst LA, Frantz RP, McGoon MD. Symptom burden, quality of life, and attitudes toward palliative care in patients with pulmonary arterial hypertension: results from a cross-sectional patient survey. J Heart Lung Transplant. 2012 Oct; 31(10):1102-8. 2270002
    View PubMed
  4. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012 Aug; 142(2):448-56. 2273129
    View PubMed
  5. Frantz RP, McGoon MD. Diagnostic dilemmas in pulmonary hypertension. Heart Fail Clin. 2012 Jul; 8(3):331-52. 2256131
    View PubMed
  6. Badesch DB, Feldman J, Keogh A, Mathier MA, Oudiz RJ, Shapiro S, Farber HW, McGoon M, Frost A, Allard M, Despain D, Dufton C, Rubin LJ, ARIES-3 Study Group. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther. 2012 Apr; 30(2):93-9. Epub 2011 Jun 20. 2187867
    View PubMed
  7. Krowka MJ, Miller DP, Barst RJ, Taichman D, Dweik RA, Badesch DB, McGoon MD. Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest. 2012 Apr; 141(4):906-15. Epub 2011 Jul 21. 2178034
    View PubMed
  8. McGoon MD, Miller DP. REVEAL: a contemporary US pulmonary arterial hypertension registry. Eur Respir Rev. 2012 Mar 1; 21(123):8-18. 2227606
    View PubMed
  9. Shapiro S, Traiger GL, Turner M, McGoon MD, Wason P, Barst RJ. Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Chest. 2012 Feb; 141(2):363-73. Epub 2011 Jul 14. 2228616
    View PubMed
  10. Benza RL, Gomberg-Maitland M, Miller DP, Frost A, Frantz RP, Foreman AJ, Badesch DB, McGoon MD. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012 Feb; 141(2):354-62. Epub 2011 Jun 16. 2228617
    View PubMed
  11. Barst RJ, McGoon MD, Elliott CG, Foreman AJ, Miller DP, Ivy DD. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation. 2012 Jan 3; 125(1):113-22. Epub 2011 Nov 15. 2225034
    View PubMed
  12. Benza RL, Gomberg-Maitland M, Frost AE, Frantz RP, Humbert M, McGoon MD. Development of prognostic tools in pulmonary arterial hypertension: Lessons from modern day registries. Thromb Haemost. 2012; 108(6):1049-60. 2288540
  13. Le RJ, Fenstad ER, Maradit-Kremers H, McCully RB, Frantz RP, McGoon MD, Kane GC. Syncope in adults with pulmonary arterial hypertension. J Am Coll Cardiol. 2011 Aug 16; 58(8):863-7. 2182967
    View PubMed
  14. Brown LM, Chen H, Halpern S, Taichman D, McGoon MD, Farber HW, Frost AE, Liou TG, Turner M, Feldkircher K, Miller DP, Elliott CG. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest. 2011 Jul; 140(1):19-26. Epub 2011 Mar 10. 2179727
    View PubMed
  15. Kane GC, Maradit-Kremers H, Slusser JP, Scott CG, Frantz RP, McGoon MD. Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension. Chest. 2011 Jun; 139(6):1285-93. Epub 2010 Nov 11. 2124387
    View PubMed
  16. Sachdev A, Villarraga HR, Frantz RP, McGoon MD, Hsiao JF, Maalouf JF, Ammash NM, McCully RB, Miller FA, Pellikka PA, Oh JK, Kane GC. Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension. Chest. 2011 Jun; 139(6):1299-309. Epub 2010 Dec 09. 2140720
    View PubMed
  17. Farber HW, Foreman AJ, Miller DP, McGoon MD. REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. Congest Heart Fail. 2011 Mar-Apr; 17(2):56-64. Epub 2011 Jan 27. 2155645
    View PubMed
  18. Burger CD, Foreman AJ, Miller DP, Safford RE, McGoon MD, Badesch DB. Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management with normative values from the National Health and Nutrition Examination Survey. Mayo Clin Proc. 2011 Feb; 86(2):105-12. 2147586
    View PubMed
  19. Frost AE, Badesch DB, Barst RJ, Benza RL, Elliott CG, Farber HW, Krichman A, Liou TG, Raskob GE, Wason P, Feldkircher K, Turner M, McGoon MD. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest. 2011 Jan; 139(1):128-37. Epub 2010 Jun 17. 2148875
    View PubMed
  20. Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, Miller DP, Nicolls MR, Zamanian RT. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010 Dec; 138(6):1383-94. Epub 2010 May 27. 2218087
    View PubMed
  21. Benza RL, Miller DP, Frost A, Barst RJ, Krichman AM, McGoon MD. Analysis of the lung allocation score estimation of risk of death in patients with pulmonary arterial hypertension using data from the REVEAL Registry. Transplantation. 2010 Aug 15; 90(3):298-305. 2103490
    View PubMed
  22. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, McGoon MD. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010 Jul 13; 122(2):164-72. Epub 2010 Jun 28. 2218086
    View PubMed
  23. Sastry BK, McGoon MD, Gibbs JS. Clinical trials for pulmonary hypertension in the developing world: pulmonary vascular disease: the global perspective. Chest. 2010 Jun; 137(6 Suppl):62S-68S. 2105338
    View PubMed
  24. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, Giles S, Feldkircher K, Miller DP, McGoon MD. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010 Feb; 137(2):376-87. Epub 2009 Oct 16. 1985314
    View PubMed
  25. Oudiz RJ, Galie N, Olschewski H, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Harrison BC, Despain D, Dufton C, Rubin LJ, ARIES Study Group. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Nov 17; 54(21):1971-81. 1982001
    View PubMed
  26. Badesch DB, McGoon MD, Barst RJ, Tapson VF, Rubin LJ, Wigley FM, Kral KM, Raphiou IH, Crater GD. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol. 2009 Oct; 36(10):2244-9. Epub 2009 Sep 01. 1959980
    View PubMed
  27. Taichman DB, McGoon MD, Harhay MO, Archer-Chicko C, Sager JS, Murugappan M, Chakinali MM, Palevsky HI, Gallop R. Wide variation in clinicians' assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension. Mayo Clin Proc. 2009 Jul; 84(7):586-92. 1965495
    View PubMed
  28. Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ, Torbicki A. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Jun 30; 54(1 Suppl):S55-66. 1965454
    View PubMed
  29. Hoeper MM, Barbera JA, Channick RN, Hassoun PM, Lang IM, Manes A, Martinez FJ, Naeije R, Olschewski H, Pepke-Zaba J, Redfield MM, Robbins IM, Souza R, Torbicki A, McGoon M. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol. 2009 Jun 30; 54(1 Suppl):S85-96. 1965455
    View PubMed
  30. McGoon MD, Kane GC. Pulmonary hypertension: diagnosis and management. Mayo Clin Proc. 2009 Feb; 84(2):191-207. 1920492
    View PubMed
  31. McGoon MD, Frost AE, Oudiz RJ, Badesch DB, Galie N, Olschewski H, McLaughlin VV, Gerber MJ, Dufton C, Despain DJ, Rubin LJ. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest. 2009 Jan; 135(1):122-9. Epub 2008 Sep 23. 1915625
    View PubMed
  32. McGoon MD, Krichman A, Farber HW, Barst RJ, Raskob GE, Liou TG, Miller DP, Feldkircher K, Giles S. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc. 2008 Aug; 83(8):923-31. 2218059
    View PubMed
  33. Frantz RP, Benza RL, Kjellstrom B, Bourge RC, Barst RJ, Bennett TD, McGoon MD. Continuous hemodynamic monitoring in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2008 Jul; 27(7):780-8. Epub 2008 Jun 02. 1894743
    View PubMed
  34. Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ, Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008 Jun 10; 117(23):3010-9. Epub 2008 May 27. 1967395
    View PubMed
  35. Ammash NM, McGoon MD, Shub A, Seward JB, Oh JK, Krowka MJ, Pellikka PA, Moon BS, Bailey KR, Wood CM, Tajik AJ. Exercise-echocardiography-derived pulmonary artery pressure slope in borderline and mild to moderate pulmonary arterial hypertension. Clin Med: Cardiol. 2008; 2:235-44. 1959738
  36. Karamanoglu M, McGoon M, Frantz RP, Benza RL, Bourge RC, Barst RJ, Kjellstrom B, Bennett TD. Right ventricular pressure waveform and wave reflection analysis in patients with pulmonary arterial hypertension. Chest. 2007 Jul; 132(1):37-43. Epub 2007 May 15. 1837111
    View PubMed
  37. Puri A, McGoon MD, Kushwaha SS. Pulmonary arterial hypertension: current therapeutic strategies. Nat Clin Pract Cardiovasc Med. 2007 Jun; 4(6):319-29. 1822529
    View PubMed
  38. Ryu JH, Krowka MJ, Pellikka PA, Swanson KL, McGoon MD. Pulmonary hypertension in patients with interstitial lung diseases. Mayo Clin Proc. 2007 Mar; 82(3):342-50. 1812283
    View PubMed
  39. Shapiro BP, McGoon MD, Redfield MM. Unexplained pulmonary hypertension in elderly patients. Chest. 2007 Jan; 131(1):94-100. 1802360
    View PubMed
  40. Barst R, Berman-Rosenzweig E, Horn E, Saiman L, Lee L, Southwick K, Kohlerschmidt D, Smith D, Gomberg-Maitland M, Weber S, Ivy D, McGoon M, Anderson Severson C, Rubenfire M, McLaughlin V, Feldman J, Tanner C, Chin K, Kingman M, Tapson V, Srinivasan A, Nob Bloodstream infections among patients treated with intravenous Epoprostenol or intravenous Treprostinil for pulmonary arterial hypertension --- seven sites, United States, 2003--2006. MMWR Morb Mortal Wkly Rep. 2007; 56:170-2. 1813241
  41. McGoon MD, David RB. American Thoracic Society: May 18-23, 2007, San Francisco, California: Ambrisentan (Letairis) for pulmonary arterial hypertension. P and T. 2007; 32(8):440. 1975795
    View PubMed
  42. Krowka MJ, Swanson KL, Frantz RP, McGoon MD, Wiesner RH. Portopulmonary hypertension: Results from a 10-year screening algorithm. Hepatology. 2006 Dec; 44(6):1502-10. 1794588
    View PubMed
  43. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, Dupuis J, Long CS, Rubin LJ, Smart FW, Suzuki YJ, Gladwin M, Denholm EM, Gail DB, National Heart, Lung and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation. 2006 Oct 24; 114(17):1883-91. 2111579
    View PubMed
  44. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation. 2006 Sep 26; 114(13):1417-31. 1786853
    View PubMed
  45. Walker AM, Langleben D, Korelitz JJ, Rich S, Rubin LJ, Strom BL, Gonin R, Keast S, Badesch D, Barst RJ, Bourge RC, Channick R, Frost A, Gaine S, McGoon M, McLaughlin V, Murali S, Oudiz RJ, Robbins IM, Tapson V, Abenhaim L, Constantine G. Temporal trends and drug exposures in pulmonary hypertension: an American experience. Am Heart J. 2006 Sep; 152(3):521-6. 1782577
    View PubMed
  46. Mahapatra S, Nishimura RA, Oh JK, McGoon MD. The prognostic value of pulmonary vascular capacitance determined by Doppler echocardiography in patients with pulmonary arterial hypertension. J Am Soc Echocardiogr. 2006 Aug; 19(8):1045-50. 1777996
    View PubMed
  47. Elliott CG, Glissmeyer EW, Havlena GT, Carlquist J, McKinney JT, Rich S, McGoon MD, Scholand MB, Kim M, Jensen RL, Schmidt JW, Ward K. Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension. Circulation. 2006 May 30; 113(21):2509-15. Epub 2006 May 22. 1769919
    View PubMed
  48. Mahapatra S, Nishimura RA, Sorajja P, Cha S, McGoon MD. Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol. 2006 Feb 21; 47(4):799-803. Epub 2006 Jan 26. 1752210
    View PubMed
  49. Urheim S, Cauduro S, Frantz R, McGoon M, Belohlavek M, Green T, Miller F, Bailey K, Seward J, Tajik J, Abraham TP. Relation of tissue displacement and strain to invasively determined right ventricular stroke volume. Am J Cardiol. 2005 Oct 15; 96(8):1173-8. Epub 2005 Sep 01. 1732277
    View PubMed
  50. Mahapatra S, Bybee KA, Bunch TJ, Espinosa RE, Sinak LJ, McGoon MD, Hayes DL. Incidence and predictors of cardiac perforation after permanent pacemaker placement. Heart Rhythm. 2005 Sep; 2(9):907-11. 1731910
    View PubMed
  51. Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005 Aug 2; 46(3):529-35. 1729838
    View PubMed
  52. Ramakrishna G, Sprung J, Ravi BS, Chandrasekaran K, McGoon MD. Impact of pulmonary hypertension on the outcomes of noncardiac surgery: predictors of perioperative morbidity and mortality. J Am Coll Cardiol. 2005 May 17; 45(10):1691-9. 1714627
    View PubMed
  53. McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA, Loyd JE. Screening, early detection, and diagnosis of pulmonary arterial hypertension - ACCP evidence-based clinical practice guidelines. Chest. 2004 Jul; 126(1 Suppl S):14S-34S. 1657385
    View PubMed
  54. Newman JH, Fanburg BL, Archer SL, Badesch DB, Barst RJ, Garcia JGN, Kao PN, Knowles JA, Loyd JE, McGoon MD, Morse JH, Nichols WC, Rabinovitch M, Rodman DM, Stevens T, Tuder RM, Voelkel NF, Gail DB. Pulmonary arterial hypertension - Future directions - Report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop. Circulation. 2004 Jun 22; 109(24):2947-52. 1653119
    View PubMed
  55. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004 Jun 16; 43(12 Suppl S):40S-47S. 1652849
    View PubMed
  56. Rubin L, Galie N, Badesch DB, Oudiz R, Simonneau G, McGoon MD, Manes A, Keogh A, Frost A, Zwicke D, Naeije R. Ambrisentan improves exercise capacity, clinical measures in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004; 169(7):A210. 1692515
    View PubMed
  57. Bhatia S, Frantz RP, Severson CJ, Durst LA, McGoon MD. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc. 2003 Oct; 78(10):1207-13. 1416937
    View PubMed
  58. Bhatia S, Morrison JF, Bower TC, McGoon MD. Pulmonary hypertension in the setting of acquired systemic arteriovenous fistulas. Mayo Clin Proc. 2003 Jul; 78(7):908-12. 1404199
    View PubMed
  59. Barst RJ, McGoon M, McLaughlin V, Tapson V, Oudiz R, Shapiro S, Robbins IM, Channick R, Badesch D, Rayburn BK, Flinchbaugh R, Sigman J, Arneson C, Jeffs R. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003 Jun 18; 41(12):2119-25. 1396841
    View PubMed
  60. McLaughlin VV, Gaine SP, Barst RJ, Oudiz RJ, Bourge RC, Frost A, Robbins IM, Tapson VF, McGoon MD, Badesch DB, Sigman J, Roscigno R, Blackburn SD, Arneson C, Rubin LJ, Rich S. Efficacy and safety of treprostinil: An Epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003 Feb; 41(2):293-9. 1318280
    View PubMed
  61. Frantz RP, McGoon MD, Severson C, Tointon S, Ballman K, Bailey KR, Heublein D, Burnett JC. Neurohumoral profiles in pulmonary hypertension: clinical and hemodynamic relationships. 5th International Congress on Lung Transplantation, Paris France, September 19-20, 2002. 1406961
  62. Langleben D, Christman BW, Barst RJ, Dias VC, Galie N, Higenbottam TW, Kneussl M, Korducki L, Naeije R, Riedel A, Simonneau G, Hirsch AM, Rich S, Robbins IM, Oudiz R, McGoon MD, Badesch DB, Levy RD, Mehta S, Seeger W, Soler M. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am Heart J. 2002 May; 143(5):E4. 1235923
    View PubMed
  63. McGoon MD. The assessment of pulmonary hypertension. Clin Chest Med. 2001 Sep; 22(3):493-508, ix. 1005435
    View PubMed
  64. Kelly AM, Porter CJ, McGoon MD, Espinosa RE, Osborn MJ, Hayes DL. Breath-holding spells associated with significant bradycardia: successful treatment with permanent pacemaker implantation. Pediatrics. 2001 Sep; 108(3):698-702. 1003765
    View PubMed
  65. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jobsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000 Mar 21; 132(6):425-34. 1314607
    View PubMed
  66. Connolly HM, McGoon MD. Obesity drugs and the heart. Curr Probl Cardiol. 1999 Dec; 24(12):749-92. 1314485
    View PubMed
  67. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology. 1999 Sep; 30(3):641-8. 1010109
    View PubMed
  68. Kopecky SL, Gersh BJ, McGoon MD, Chu CP, Ilstrup DM, Chesebro JH, Whisnant JP. Lone atrial fibrillation in elderly persons: a marker for cardiovascular risk. Arch Intern Med. 1999 May 24; 159(10):1118-22. 115521
    View PubMed
  69. Castro PF, Bourge RC, McGiffin DC, Benza RL, Fan P, Pinkard NB, McGoon MD. Intrapulmonary shunting in primary pulmonary hypertension: an observation in two patients treated with epoprostenol sodium. Chest. 1998 Jul; 114(1):334-6. 106871
    View PubMed
  70. Yeo TC, Dujardin KS, Tei C, Mahoney DW, McGoon MD, Seward JB. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol. 1998 May 1; 81(9):1157-61. 105264
    View PubMed
  71. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997 Aug 28; 337(9):581-8. 99634
    View PubMed
  72. Hinderliter AL, Willis PW 4th, Barst RJ, Rich S, Rubin LJ, Badesch DB, Groves BM, McGoon MD, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Koch G, Li S, Clayton LM, Jobsis MM, Blackburn SD Jr, Crow JW, Long Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation. 1997 Mar 18; 95(6):1479-86. 101915
    View PubMed
  73. McGoon MD. Prognosis and natural history. Lung Biol Health Dis. 1997; 99:305-317. 101440
  74. Tei C, Dujardin KS, Hodge DO, Bailey KR, McGoon MD, Tajik AJ, Seward SB. Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr. 1996 Nov-Dec; 9(6):838-47. 98616
    View PubMed
  75. Lloyd MA, Hayes DL, Holmes DR Jr, Stanson AW, Espinosa RE, Osborn MJ, McGoon MD. Extraction of the Telectronics Accufix 330-801 atrial lead: the Mayo Clinic experience. Mayo Clin Proc. 1996 Mar; 71(3):230-4. 95568
    View PubMed
  76. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jobsis MM, Blackburn SD, Shortino D, Crow JW, Primary Pulmonary Hypertension St A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996 Feb 1; 334(5):296-301. 2273895
    View PubMed
  77. Cannan CR, McGoon MD, Holmes DR Jr, Lerman A. Altered coronary endothelial function in a patient with asymptomatic left ventricular dysfunction. Int J Cardiol. 1996 Feb; 53(2):147-51. 95675
    View PubMed
  78. Abenheim L, Moride Y, Brenot F, McGoon MD, et al for the international Primary Pulmonary Hypertension Study Group. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Eng J Med. 1996; 335:609-16. 1137954
  79. McGoon MD. Medical treatment of pulmonary hypertension. Cardiologia. 1995 Aug; 40(8):561-77. 94160
    View PubMed
  80. Sueta CA, Gheorghiade M, Adams KF, Bourge RC, Murali S, Uretsky BF, Pritzker MR, McGoon MD, Butman SM, Grossman SH, Crow JW, Shaffer CL, Thorn MD. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Am J Cardiol. 1995 Jan 19; 75:A34-A43. 91669
  81. Enriquez-Sarano M, Tajik AJ, Schaff HV, Orszulak TA, McGoon MD, Bailey KR, Frye RL. Echocardiographic prediction of left ventricular function after correction of mitral regurgitation: results and clinical implications. J Am Coll Cardiol. 1994 Nov 15; 24(6):1536-43. 1314000
    View PubMed
  82. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med. 1994 Sep 15; 121(6):409-15. 88964
    View PubMed
  83. Porter CJ, McGoon MD, Espinosa RE, Osborn MJ, Hayes DL. Apparent breath-holding spells associated with life-threatening bradycardia treated by permanent pacing. Ped Cardiol. 1994; 15:260. 143873
  84. Espinosa RE, Hayes DL, Vlietstra RE, Osborn MJ, McGoon MD. The Dotter retriever and pigtail catheter: efficacy in extraction of chronic transvenous pacemaker leads. Pacing & Clinical Electrophysiology. 1993 Dec; 16(12):2337-42. 84988
    View PubMed
  85. Murphy JG, Gersh BJ, Mair DD, Fuster V, McGoon MD, Ilstrup DM, McGoon DC, Kirklin JW, Danielson GK. Long-term outcome in patients undergoing surgical repair of tetralogy of Fallot. N Engl J Med. 1993 Aug 26; 329(9):593-9. 85961
    View PubMed
  86. Rubin LJ, Barst RJ, Kaiser LR, Koerner SK, Loyd JE, McGoon MD, Pietra G, Rich S, Rubenfire M, Theodore J. Primary pulmonary hypertension. Chest. 1993; 104:236-50. 1137952
    View PubMed
  87. McGoon MD, Frantz RP. Techniques of immunosuppression after cardiac transplantation. Mayo Clin Proc. 1992 Jun; 67:586-595. 79920
    View PubMed
  88. Porter CB, Fukushige J, Hayes DL, McGoon MD, Osborn MJ, Puga FJ. Permanent antitachycardia pacing for chronic atrial tachyarrhythmias in postoperative pediatric patients. Pacing Clin Electrophysiol. 1991 Nov; 14(11 Pt 2):2056-7. 78790
    View PubMed
  89. Iqbal A, Gibbons RJ, McGoon MD, Steiroff S, Frohnert PT, Velosa JA. Noninvasive assessment of cardiac risk in insulin-dependent diabetic patients being evaluated for pancreatic transplantation using thallium-201 myocardial perfusion scintigraphy. Transplant Proc. 1991 Feb; 23(1 Pt 2):1690-1. 1313704
    View PubMed
  90. Fukushige J, Porter CJ, Hayes DL, McGoon MD, Osborn MJ, Vlietstra RE. Antitachycardia pacemaker treatment of postoperative arrhythmias in pediatric patients. PACE. 1991; 14:546-56. 146463
    View PubMed
  91. Murphy JG, Gersh BJ, McGoon MD, Mair DD, Porter CJ, Ilstrup DM, McGoon DC, Puga FJ, Kirklin JW, Danielson GK. Long-term outcome after surgical repair of isolated atrial septal defect. Follow-up at 27 to 32 years. N Engl J Med. 1990 Dec 13; 323(24):1645-50. 1993018
    View PubMed
  92. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, Diehl JH, Crow J, Long W. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 1990 Apr 1; 112(7):485-91. 72361
    View PubMed
  93. McGoon MD, Shapland JE, Salo R, Pederson B, Olive A. The feasibility of utilizing the systolic pre-ejection interval as a determinant of pacing rate. J Am Coll Cardiol. 1989 Dec; 14(7):1753-8. 70401
    View PubMed
  94. Redfield MM, Edwards BS, McGoon MD, Heublein DM, Aarhus LL, Burnett JC Jr. Failure of atrial natriuretic factor to increase with volume expansion in acute and chronic congestive heart failure in the dog. Circulation. 1989 Sep; 80(3):651-7. 69756
    View PubMed
  95. McGoon MD. Rate-responsive pacing using an impedance lead. J Electrocardiol. 1989; 22 Suppl:223. 70589
    View PubMed
  96. Kopecky SL, Gersh BJ, McGoon MD, Mair DD, Porter CJ, Ilstrup DM, McGoon DC, Kirklin JW, Danielson GK. Long-term outcome of patients undergoing surgical repair of isolated pulmonary valve stenosis. Follow-up at 20-30 years. Circulation. 1988 Nov; 78(5 Pt 1):1150-6. 66776
    View PubMed
  97. Nishimura RA, McGoon MD, Schaff HV, Giuliani ER. Chronic aortic regurgitation: indications for operation--1988. Mayo Clin Proc. 1988 Mar; 63(3):270-80. 64937
    View PubMed
  98. Horowitz SF, Matza D, Machac J, Alexopoulos D, McGoon MD, Gibbons RJ, Fuster V. Right and left ventricular functional response to supine exercise in patients with asymptomatic mitral regurgitation. J Am Coll Cardiol. 1988 Feb; 11(Suppl A):229A. 64911
  99. McGoon MD, Fetter J. Noninvasive conversion of a fixed-rate demand pacemaker to activity mode: a method for assessing the clinical effect of rate-responsiveness. Mayo Clin Proc. 1987 Oct; 62(10):882-5. 62724
    View PubMed
  100. Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR, Ilstrup DM, Frye RL. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med. 1987 Sep 10; 317(11):669-74. 62991
    View PubMed
  101. McGoon MD, Vlietstra RE. Acute hemodynamic response to the S2-serotonergic receptor antagonist, ketanserin, in patients with primary pulmonary hypertension. Int J Cardiol. 1987 Mar; 14(3):303-9. 61354
    View PubMed
  102. Talierco CP, McGoon MD, Vlietstra RE, Porter C-BJ, Osborn MJ, Danielson GK. Cardiac pacing after the Fontan procedure: 1973-1986. Clin Prog Electrophysiol Pacing. 1986; 4:246. 1313040
  103. McGoon MD, Callahan MJ, Gersh BJ. Optimal timing of valvular surgery. Appl Cardiol. 1986; 14:19-24. 1137938
  104. Mills TJ, Seward JB, McGoon MD, Callahan MJ. Platypnea-orthodeoxia: assessment with a unique cardiac catheterization procedure. Cathet Cardiovasc Diagn. 1986; 12(2):100-2. 58354
    View PubMed
  105. Nishimura RA, McGoon MD, Shub C, Miller FA Jr, Ilstrup DM, Tajik AJ. Echocardiographically documented mitral-valve prolapse. Long-term follow-up of 237 patients. N Engl J Med. 1985 Nov 21; 313(21):1305-9. 56026
    View PubMed
  106. Taliercio CP, Vlietstra RE, McGoon MD, Porter CJ, Osborn MJ, Danielson GK. Permanent cardiac pacing after the Fontan procedure. J Thorac Cardiovasc Surg. 1985 Sep; 90(3):414-9. 55457
    View PubMed
  107. Shub C, Vlietstra RE, McGoon MD. Selection of optimal drug therapy for the patient with angina pectoris. Mayo Clin Proc. 1985 Aug; 60(8):539-48. 55244
    View PubMed
  108. Lemery R, McGoon MD, Edwards WD. Cardiac sarcoidosis: a potentially treatable form of myocarditis. Mayo Clin Proc. 1985 Aug; 60(8):549-54. 55245
    View PubMed
  109. McGoon MD, Edwards WD. Primary pulmonary hypertension: current status. Mod Concepts Cardiovasc Dis. 1985 Jun; 54:29-33. 54869
  110. McGoon MD, Vlietstra RE. Vasodilator therapy for primary pulmonary hypertension. Mayo Clin Proc. 1984 Oct; 59(10):672-7. 52278
    View PubMed
  111. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984 Oct; 70(4):580-7. 52447
    View PubMed
  112. Vlietstra RE, McGoon MD. Beta-adrenergic blockers. Choosing among them. Postgrad Med. 1984 Sep 1; 76:70-80. 52178
    View PubMed
  113. Sugrue DD, Wood DL, McGoon MD. Carotid sinus hypersensitivity and syncope. Mayo Clin Proc. 1984 Sep; 59(9):637-40. 52051
    View PubMed
  114. McGoon MD, Vanhoutte PM. Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine. J Clin Invest. 1984 Sep; 74(3):828-33. 52252
    View PubMed
  115. McGoon MD, Fuster V, McGoon DC, Pumphrey CW, Pluth JR, Elveback LR. Aortic and mitral valve incompetence: long-term follow-up (10 to 19 years) of patients treated with the Starr-Edwards prosthesis. J Am Coll Cardiol. 1984 Apr; 3(4):930-8. 51717
    View PubMed
  116. Nishimura RA, McGoon MD, Shub C, Ilstrup DM, Tajik AJ. Long-term follow-up of mitral valve prolapse documented by M-mode echocardiography in 283 patients. Circulation. 1984; 70. 143864
  117. McGoon MD, Seward JB, Vlietstra RE, Choo MH, Moyer TP, Reeder GS. Haemodynamic response to intravenous hydralazine in patients with pulmonary hypertension. Br Heart J. 1983 Dec; 50(6):579-85. 49887
    View PubMed
  118. Fuster V, Pumphrey CW, McGoon MD, Chesebro JH, Pluth JR, McGoon DC. Systemic thromboembolism in mitral and aortic Starr-Edwards prostheses: a 10-19 year follow-up. Circulation. 1982 Aug; 66(PART II):157-161. 45911
  119. McGoon MD, Vlietstra RE, Holmes DR, Osborn JE. The clinical use of verapamil. Mayo Clin Proc. 1982 Aug; 57(8):495-510. 45928
    View PubMed
  120. McGoon MD, Maloney JD, McGoon DC, Danielson GK. Long-term endocardial atrial pacing in children with postoperative bradycardia-tachycardia syndrome and limited ventricular access. Am J Cardiol. 1982 May; 49(7):1750-7. 45549
    View PubMed
  121. Bo-Linn GW, Anderson DJ, Anderson KC, McGoon MD. Percutaneous central venous catheterization performed by medical house officers: a prospective study. Cathet Cardiovasc Diagn. 1982; 8(1):23-9. 1137936
    View PubMed
  122. McGoon MD, Benedetto PW, Greene BM. Complications of percutaneous central venous catheterization: a report of two cases and review of the literature. Johns Hopkins Med J. 1979 Jul; 145(1):1-6. 1137931
    View PubMed
  123. McGoon MD, Fulton RE, Davis GD, Ritter DG, Neill CA, White RI Jr. Systemic collateral and pulmonary artery stenosis in patients with congenital pulmonary valve atresia and ventricular septal defect. Circulation. 1977 Sep; 56(3):473-9. 34606
    View PubMed